ONN® - OncLive News Network®

Dr. Ghassan Abou-Alfa leads a small panel including Dr. Robert Lewandowksi and Dr. Amit Singal in a multidisciplinary discussion of hepatocellular carcinoma and updates to the treatment armamentarium.

Harry Yoon, MD and Nabil Saba, MD, FACP, discuss recent data on novel regimens for first-line treatment of advanced/metastatic ESCC, including the immunotherapy regimen tislelizumab.

Hans Hammers, MD, PhD, and Moshe Ornstein, MD, MA, discuss data updates in advanced renal cell carcinoma (RCC) that were presented at the recent 2022 International Kidney Cancer Symposium.

Join us LIVE at this year's 2022 ASH Annual Meeting and Exposition! OncLive® will broadcast a series of interviews with top thought leaders in multiple myeloma, acute myeloid leukemia, non-Hodgkin lymphoma, graft-vs-host disease, chronic lymphocytic leukemia, and myeloproliferative neoplasms. The experts will share their insights and reactions to the pivotal data presented during the conference.

Dr Nikhil Khushalani reviews recent data updates for the treatment of non-melanoma skin cancers focusing on cutaneous squamous cell carcinoma and basal cell carcinoma.

Drs Jeanny B. Aragon-Ching and Srikala Sridhar review key updates in the management of urothelial carcinoma from data presented in 2022.

Expert oncologists share their perspectives on key updates in the management of hormone receptor–positive metastatic breast cancer from the past year.

Join us LIVE at this year's 2022 ESMO Congress! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Aditya Bardia, MD, MPH discusses the present and prospective clinical applications of ctDNA monitoring informed by promising data presented at the ASCO 2022 Annual Meeting.

Expert oncologists incorporate personal experience with data from the recent ASCO 2022 annual meeting to highlight optimal testing and management strategies in breast cancer.

Omid Hamid, MD, and Ryan Sullivan, MD, discuss new updates in uveal melanoma, and an exciting, recently approved agent for treatment of metastatic disease.

Expert oncologists reflect on recent clinical trial data to elucidate the evolving treatment landscape of checkpoint inhibition in non–small cell lung cancer.

Experts discuss current and investigational antibody drug conjugates (ADCs) in non-small cell lung cancer treatment and how they affect therapy approaches.

Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.

Vijayakrishna Gadi, MD, PhD, provides an overview of recent advancements in the treatment of HER2+ metastatic breast cancer with special consideration for challenges in the management of patients with CNS metastases.

Jae Park, MD, reviews the current treatment landscape and emerging options for treating adults with relapsed/refractory B-cell acute lymphoblastic leukemia

Join us LIVE at this year's 2022 ASCO Annual Meeting! OncLive® will broadcast a series of interviews with top thought leaders in breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, and gynecologic malignancies. The experts will share their insights and reactions to the pivotal data presented during the conference.

Experts Joyce A. O’Shaughnessy, MD, and Sara A. Hurvitz, MD, provide comprehensive updates on the optimal workup and management of patients with breast cancer.

Expert perspectives on novel management of HER2+ metastatic breast cancer in the context of recent clinical trials and FDA approvals.

Join us LIVE at this year's 2022 Genitourinary Cancers Symposium! OncLive® will broadcast a series of interviews with top thought leaders across cancers of the bladder, prostate, and kidney. The experts will share their insights and reactions to the pivotal data presented during the conference.

How ctDNA testing is being investigated and used in pancreatic and colorectal cancer in the era of precision medicine.

Two experts lead a discussion about chronic lymphocytic leukemia (CLL), focusing on updates in management and special considerations when treating with BTK inhibitors.

Drs Carl M. Gay and Jared Weiss highlight novel treatment advances for newly diagnosed and relapsed/refractory small cell lung cancer.

Hossein Borghaei, DO, MS, and Martin Reck, MD, PhD, highlight recent advances and use of immune checkpoint inhibitors in the treatment of first-line metastatic non-small cell lung cancer.

Shared insight on the clinical impact circulating tumor DNA testing has had on the management of patients with breast cancer.

Gary Ulaner, MD, PhD and Jeremy Force, DO discuss the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18F-FES-PET imaging in diagnosis and treatment of ER-positive breast cancer and in improving patient outcomes.

Experts review key updates in multiple myeloma management from the ASH 2021 annual meeting.

As part of its Speaking Out video series, CURE spoke with Rebecca Moroose, MD, from Orlando Health Cancer Institute, and Virginia G. Kaklamani, MD, from UT Health San Antonio, about the National Comprehensive Cancer Network guidelines and what they mean for patients.